Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating income | -$16.2M | -$32.7M | -$67.1M | -$89.2M | -$84.1M |
| Net income | -$16.2M | -$31.2M | -$60.4M | -$80.6M | -$77.9M |
| EPS (diluted) | -$9.32 | -$7.56 | -$2.74 | -$2.38 | -$2.02 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$14.0M | -$30.1M | -$42.6M | -$65.7M | -$63.7M |
| Capital expenditures | $238K | $2.17M | $1.29M | $2.77M | $1.67M |
| Free cash flow | -$14.2M | -$32.3M | -$43.9M | -$68.4M | -$65.3M |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $99.6M | $29.5M | $36.0M | $39.8M | $41.5M |
| Total assets | $107M | $181M | $138M | $197M | $130M |
| Total liabilities | $7.88M | $10.8M | $17.1M | $19.8M | $17.2M |
| Shareholders' equity | -$23.8M | $170M | $121M | $177M | $113M |
| Retained earnings | -$24.9M | -$56.0M | -$116M | -$197M | -$275M |
| Shares (wtd avg diluted) | 1.74M | 4.12M | 22.1M | 33.8M | 38.5M |
Every figure is extracted from Acrivon Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.